Roche (RHHBY.US) deploys over 3500 NVIDIA Corporation GPUs, intends to build an "AI factory" to reshape the entire drug development chain.
Roche has completed the deployment of a large-scale AI infrastructure globally, with its core being a new "AI factory" driven by 2176 NVIDIA Blackwell GPUs.
Roche (RHHBY.US) has completed the deployment of a large-scale AI infrastructure globally, with its core being a new "AI factory" powered by 2176 NVIDIA Corporation (NVDA.US) Blackwell GPUs to facilitate the development of new drugs and diagnostic technologies. By deploying these cutting-edge computing units at multiple sites in the United States and Europe, Roche currently holds over 3500 GPUs, making it the largest-scale deployment of its kind in the pharmaceutical industry.
Roche has stated that it has used NVIDIA Corporation's BioNeMo platform for research and development to improve its "Lab-in-the-Loop" mode, connecting biological and chemical experiments with Roche's artificial intelligence models. This helps scientists test hypotheses on a large scale, accelerate research progress, and achieve discoveries that would not be possible otherwise.
In addition to traditional drug development, the functions of this AI factory extend to several core business areas such as optimizing clinical trials, digital pathology, and genomic data analysis. Roche plans to use the NVIDIA Parabricks platform to process massive amounts of genetic sequence data and utilize digital pathology imaging technology to identify tiny disease features, enabling the large-scale application of precision medicine.
At the same time, by introducing NVIDIA Corporation's NeMo Guardrails technology, Roche is developing conversational AI that meets medical-grade security standards to assist researchers in accessing and analyzing experimental data more efficiently. This AI penetration across the entire industry chain not only enhances enterprise operational efficiency but also provides powerful computing support for the development of future personalized medical solutions.
Roche's significant increase in computing power also indicates that the global biopharmaceutical industry is officially entering the era of "computing competition." Previously, pharmaceutical giants such as Eli Lilly (LLY.US) and Novo Nordisk A/S Sponsored ADR Class B (NVO.US) have each launched their own supercomputing platforms, competing to use high-performance computing to accelerate molecular design.
Related Articles
HK Stock Market Move | The automobile stocks continue to rise recently, with several heavyweight new cars waiting to be launched. Institutions point out that there is potential to catalyze the release of automobile market demand.
HK Stock Market Move | WECON HOLDINGS (01793) resumed trading and dropped by 20%, with the controlling shareholder offering a discount of about 13.8% to privatize the company.
CMSC: Expansion of Optical Module Production and Development Trend of Technological Iteration, Suggest Focusing on the Optical Module Equipment Industry.
HK Stock Market Move | The automobile stocks continue to rise recently, with several heavyweight new cars waiting to be launched. Institutions point out that there is potential to catalyze the release of automobile market demand.
HK Stock Market Move | WECON HOLDINGS (01793) resumed trading and dropped by 20%, with the controlling shareholder offering a discount of about 13.8% to privatize the company.
CMSC: Expansion of Optical Module Production and Development Trend of Technological Iteration, Suggest Focusing on the Optical Module Equipment Industry.
